Top Markets
Coin of the day
Poniard Pharmaceuticals, Inc. Poniard Pharmaceuticals, Inc.

Poniard Pharmaceuticals, Inc.

PARD
주식 순위 #42764
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the... Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
주가
$0.0001
마지막 동기화: 2026-08-11
시가총액
$150.00
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Poniard Pharmaceuticals, Inc. (PARD)

카테고리

Poniard Pharmaceuticals, Inc. (PARD)의 EPS
2026 기준 EPS TTM: 0
Poniard Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Poniard Pharmaceuticals, Inc.의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS